KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Other Gross PP&E Adjustments (2020 - 2026)

AbCellera Biologics filings provide 7 years of Other Gross PP&E Adjustments readings, the most recent being $352.0 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 15.52% to $352.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $352.0 million through Mar 2026, up 15.52% year-over-year, with the annual reading at $332.6 million for FY2025, 11.19% up from the prior year.
  • Other Gross PP&E Adjustments hit $352.0 million in Q1 2026 for AbCellera Biologics, up from $332.6 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $352.0 million in Q1 2026 and bottomed at $116.2 million in Q1 2022.
  • Average Other Gross PP&E Adjustments over 5 years is $240.4 million, with a median of $231.2 million recorded in 2024.
  • The largest annual shift saw Other Gross PP&E Adjustments surged 274.43% in 2022 before it fell 21.97% in 2025.
  • AbCellera Biologics' Other Gross PP&E Adjustments stood at $154.9 million in 2022, then surged by 49.44% to $231.5 million in 2023, then rose by 29.22% to $299.1 million in 2024, then increased by 11.19% to $332.6 million in 2025, then rose by 5.86% to $352.0 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Other Gross PP&E Adjustments are $352.0 million (Q1 2026), $332.6 million (Q4 2025), and $223.4 million (Q3 2025).